source
- InnoCare’s TYK2 inhibitor soficitinib meets primary endpoint in phase 2 vitiligo trialInnoCare Pharma announced that its TYK2 inhibitor soficitinib achieved the primary endpoint in a phase 2 study of non‑segmental vitiligo conducted at sites in China. The trial evaluated daily oral…
- Biopharma layoffs may exceed 14,000 jobs in H1 as Takeda, BioNTech and Viatris cut staffBiopharma firms are preparing for a wave of job cuts in the first half of 2026, with total layoffs projected to affect more than 14,000 employees, according to data compiled by BioSpace. The bulk…